Revenue
2021
2022
2023
2024
2025
Verrica Pharmaceuticals Inc. (VRCA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M | — | — | — | — |
| Research & development | $8.9M | $11.8M | $20.3M | $12.2M | $15.9M | $15.7M | $15.4M | $12.8M | $3.7M |
| Operating expenses | $47.8M | $73.5M | $70.9M | $30.3M | $42.9M | $40.2M | $30.1M | $21.9M | $4.5M |
| Operating income | −$12.2M | −$65.9M | −$65.8M | −$21.3M | −$30.9M | −$40.2M | −$30.1M | −$21.9M | −$4.5M |
| Net income | −$17.9M | −$76.6M | −$67.0M | −$24.5M | −$35.1M | −$42.7M | −$28.2M | −$20.6M | −$4.5M |
| Basic EPSper diluted share | -$1.68 | -$14.78 | -$1.48 | -$0.72 | -$1.30 | -$1.71 | -$1.13 | -$1.41 | -$1.56 |
| Diluted EPSper diluted share | -$1.68 | -$14.78 | -$1.48 | -$0.72 | -$1.30 | -$1.71 | -$1.13 | -$1.41 | -$1.56 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 25, 2025Form 4 | Zawitz DavidChief Operating Officer | BuyCommon Stock | 10.0K | $4.24 | $42.4K | 21.0K |
| Nov 25, 2025Form 4 | Zawitz DavidChief Operating Officer | BuySeries C Warrant (right to buy) · derivative | 2.5K | — | — | 2.5K |
| Nov 25, 2025Form 4 | Rieger JaysonCEO and President | BuyCommon Stock | 94.3K | $4.24 | $399.9K | 182.6K |
| Nov 25, 2025Form 4 | Rieger JaysonCEO and President | BuySeries C Warrant (right to buy) · derivative | 23.6K | — | — | 23.6K |
| Nov 25, 2025Form 4 | Rosenberg Noah L.CMO | BuyCommon Stock | 2.4K | $4.24 | $10.0K | 2.4K |